News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History
Sebastian Schmidt: Declining mortality in lung cancer – a beacon of hope
Photo taken from Sebastian Schmidt/LinkedIn
01/11/2023 14:55

Sebastian Schmidt: Declining mortality in lung cancer – a beacon of hope

Sebastian Schmidt, Head of Strategy and Medical Affairs Computed Tomography at Siemens Healthineers, posted on LinkedIn:

“Declining mortality in lung cancer – a beacon of hope.

I made a little chart for my presentation at the European Society of Thoracic Imaging (ESTI) conference in Berlin today that I wanted to share with you.

The chart shows an analysis of the US cancer statistics (SEER data). The orange line is the incidence per 100k inhabitants (cases of lung cancer), scale on the left. The black line is lung cancer mortality (deaths from lung cancer). The grey bars are the Mortality/Incidence ratio, which gives an estimate of what percentage of patients die from the disease.

What do we see:

– Mortality and incidence were largely parallel over a longer time (actually longer than the period shown here). The Mortality/Incidence ratio therefore almost constantly >80%, little to no improvement. Consider this is a time period when we saw enormous improvements in breast cancer and many other cancers.
– Late 90s, incidence started to go down. This is surely an effect of the tobacco control measures introduced in the 70s. Tobacco control works, but of course with a 20-year latency. Mortality still parallel. MIR above 80%.
– Around 2014, the MIR started declining – mortality went down faster than incidence. This is a sign that survival of patient finally improves, after so many years of little change.

Two effects likely have contributed: New drugs, mainly immuno-oncological, improved survival. And the USPSTF recommended lung screening, the screening programs started, which increased the share of early-stage diagnosis.

Could overdiagnosis play a role? Rather unlikely – the typical sign for large-scale overdiagnosis in screening programs is increasing incidence with constant mortality. We don’t see increasing incidence here – the curve declines evenly, following the reduction in smoking 20 years earlier. And the mortality is obviously declining.

This is positive news and should encourage more countries to take up lung cancer screening. ”

 

Source: Sebastian Schmidt/LinkedIn

 

cancer ESTI 2023 Lung cancer OncoDaily Oncology Sebastian Schmidt
Blog
16:27 30/11/23
David Lubarsky: 4 Ms
Drugs
16:23 30/11/23
Mariana Brandao: My comment on the ARTEMIDE-01 phase I trial testing a new bispecific anti-PD-1/anti-TIGIT antibody called Rilvegostomig
Blog
16:18 30/11/23
Do you want to be part of the first-ever national cancer innovation accelerator initiative with public support from The White House? - CancerX Moonshot
Opinion
16:11 30/11/23
Gavin Preston: If thinking of going into medicine to get rich, forget it
Blog
16:04 30/11/23
Two charities will co-fund a major £5.5 million research programme called Stratified Medicine Paediatrics 2 - The Institute of Cancer Research
Blog
15:58 30/11/23
Aju Mathew: Rising numbers of hepatocellular carcinoma in India
Blog
15:51 30/11/23
Bente Mikkelsen: This is the latest edition of the IARC handbook series and covers the topic of oral cancer prevention
Blog
15:43 30/11/23
Rebekka K. Schneider: Our research will be supported by an European Research Council (ERC) consolidator grant
Blog
15:39 30/11/23
Otilia Ciobanu: Review on the potential of targeting the subventricular zone for improved outcomes in high-grade gliomas
Blog
15:33 30/11/23
Andre Lopes Carvalho: I had the incredible opportunity to celebrate the 20th anniversary of ZORA
Drugs
15:29 30/11/23
David Steensma: Randomized STIMULUS-MDS1 trial didn't meet endpoint
Blog
15:25 30/11/23
Monica M. Bertagnolli: One of my priorities is ensuring all people are represented in clinical trials
Insight
Positive
Societies
Career